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We are pleased to respond to the letter of Coste at al. [1] as 
follows. Nowhere in our article is any claim made to analyse 
the problem of symptoms reported with the new formulation 
of  Levothyrox®. Our sole aim was to challenge scientifi-
cally the principle of using an average bioequivalence (ABE) 
approach to document a switchability issue. This is a par-
ticular concern, given that substitution of a new formulation 
was imposed on several million patients.
First, we address the question of correcting (or not) the 
raw data for basal values of thyroxine (T4). Our article is 
neither misplaced nor misleading in this regard, and, for 
the avoidance of doubt, we direct readers to the 2010 Euro-
pean Union (EU) guideline [2]. It is a requirement of this 
guideline that a baseline correction should be applied to 
the variable area under the curve for products containing 
endogenous compounds as active constituents. The guideline 
states explicitly “If the substance being studied is endoge-
nous, the calculation of pharmacokinetic parameters should 
be performed using baseline correction so that the calcu-
lated pharmacokinetic parameters refer to the additional 
concentrations provided by the treatment”. Moreover, the 
guideline further qualifies this requirement in stating: “The 
exact method for baseline correction should be pre-specified 
and justified in the study protocol. In general, the stand-
ard subtractive baseline correction method, meaning either 
subtraction of the mean of individual endogenous pre-dose 
concentrations or subtraction of the individual endogenous 
predose AUC, is preferred”. We have followed the guideline 
to the letter and note that the US Food and Drug Administra-
tion guideline [3] gives a similar direction.
Furthermore, we draw attention to the fact that the French 
Regulatory Authorities’ evaluation dossier for  Levothyrox® 
explicitly endorsed this baseline correction [4]. Neverthe-
less, it is the case that the actual methods used to correct 
baseline concentrations of endogenous compounds have 
been debated in the literature. In a review on the methodol-
ogy adopted to assess the bioequivalence of levothyroxine 
[5], it was concluded that the so-called correction Method 
1, comprising subtraction from each T4 concentration of the 
mean of control concentrations, is the most appropriate and 
was, indeed, cited in the US Food and Drug Administration 
guideline [3]. This method we followed precisely.
Second, in their letter to the Editor, Coste et al. stated 
“Furthermore, the authors use results obtained from 
adjusted IER, rather than from unadjusted IER, to affirm 
the “fact that more than 50% of individuals were outside the 
a priori bioequivalence range (0.90–1.11)”. In response, we 
confirm the soundness of this approach, as the EU guide-
line indicates that it is only “In rare cases where substantial 
increases over baseline endogenous levels are seen, base-
line correction may not be needed”. Even when consider-
ing only the unadjusted baseline area under the curve, the 
number of subjects outside the a priori acceptance interval 
of 0.90–1.11 is still sufficiently high (17%) to constitute a 
red warning signal of possible non-individual bioequiva-
lence. This might be suspected when the percentage exceeds 
10% [6]. In addition, it has been alleged that the applica-
tion of criteria for determination of bioequivalence, without 
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accounting for endogenous T4 levels, resulted in a failure to 
identify products that differed by as much as 25–33% [7].
We question this technical polemical argument, which 
fails to address the main messages conveyed by our article. 
The article did not challenge the data analysis, as conducted 
by the company; in fact, we endorsed this when stating, “it 
is acknowledged that the trial and analyses were conducted 
professionally according to current EU guidelines” [8].
To be clear, what we are challenging is the validity of an 
ABE investigation to impose, administratively, substitution 
of an older by a newly formulated product for almost 3 mil-
lion patients. We make this challenge because an ABE study 
is not intended for and therefore should not be used to guar-
antee the switchability within patients of two formulations.
In summary, what must be questioned is that a new for-
mulation, possibly highly variable in its pharmacokinetic 
profile (implicitly indicated by the 216 subjects planned and 
used to demonstrate the ABE [9]), should be marketed on the 
basis of an ABE, for a drug like levothyroxine, with a narrow 
therapeutic index [10–12], without any further evaluation or 
precautions.
In a future publication, we shall challenge this use of an 
atypically large number of subjects (204 for the present ABE 
trial). Further, we will propose that this effectively nullifies 
the necessarily precautionary intention of the EU guideline, 
when recommending shortening the a priori acceptance 
interval from 0.80–1.25 to 0.90–1.11.
Finally, we accept that there is neither conspiracy nor 
malice on either side of this debate, but rather a difference 
of judgement on data derived and conclusions drawn. It is 
scientific argument that must fuel this crucial debate, with its 
welfare considerations, and not media opinions, when these 
are not based on sound science.
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